The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Semaglutide, which is essentially an GLP-1 agonist. It causes the release of more GLP-1. It's being used to treat type II diabetes, which is insulin resistant diabetes. This is different than type I diabetes where people don't actually make insulin. It's also being used as a drug to reduce obesity. And it seems pretty effective at least in certain populations.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And these are the semaglutide drugs that are involved in-- they tap into these glucagon related GLP-1 pathways. And it is a story that we've talked about a little bit on the podcast before. But many people, I imagine, probably haven't heard that conversation. I would simply like to know what you think about these drugs. They obviously adjust the way that glucose and insulin are managing energy, both in the body and the brain, and can produce weight loss.
I know there's a lot of excitement nowadays about these semaglutide yeah um analoges because they do seem very effective in blocking hunger especially in type two diabetics
you know semi Glu OIC was approved longer than that for four type 2 diabetics helping with you know glucose control and helping with glucose utilization uh and what they found you know as a side effect was that these people were losing weight
at the other end of the spectrum we clearly know now how to do it with drugs and that's really changed I think it really started in 2014 when liraglutide came out but clearly semaglutide was the GameChanger and that's three years ago was when we saw the pivot from semaglutide as just a diabetic drug to an obesity drug
and they've successfully treated people with type 2 diabetes and like all things or is often the case you sort of notice something in treating one subset of patients that gives you an insight into treating another and so basically as people with type 2 diabetes were treated with this class of drug you notice that it wasn't just improving their diabetes they were also losing weight and that led to what became a set of dedicated experiments to test the efficacy of these drugs in non-diabetic obese patients
whereas today I I I can't imagine too many people haven't heard the words OIC um or some of its derivatives but I think OIC might be one of the most recognized um of these drugs